Chronic hepatitis c
Conditions
Interventions
Peginterferon plus ribavirin for 48-72 weeks
Sponsors
Saitama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following chronic hepatitis C patients with serogroup 1 and high viral load were eligible to enter the trial 1) From 18 years old or over 2)Chronic hepatitis C 3)The presence of the liver biopsy is not asked 4)HCV RNA>=5LogIU/mL 5)Platelet count >=90,000/micro L 6)WBC count>=3,000/micro L. Neutrophil count >=1,500/micro L. Hemoglobin concentration >=12g/dL. 7)The presence of the IFN treatment history is not asked 8)Patients who provided written informed consents to participate the study prior to enrollment
Exclusion criteria
Exclusion criteria: The following patients were excluded 1)Women of childbearing potential and pregnancy, lactating woman 2) allergic to ribavirin or nucleoside analogues 3)an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia) 4)hemoglobinopathy(thalassemia, sickle cell disease) 5) severe renal disease, Ccr <50ml/min 6) severe depression or psychosomatic disorders 7)severe liver disease 8) autoimmune hepatitis or HBV 9) drug allergy against interferon 10) Allergic to vaccine or biological preparations 11) Concomitant herbal medication of Sho-saikoto 12) history of interstitial pneumonia 13)Other conditions considered inappropriate by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between IL28B gene polymorphism and virological response to Peginterferon plus ribavirin treatment | — |
Countries
Japan
Contacts
Public ContactKouji Yakabi
Saitama Medical Center Division of Gastroenterology and Hepatology,internal Medicine
Outcome results
None listed